
Aptargroup (ATR) Stock Forecast & Price Target
Aptargroup (ATR) Analyst Ratings
Bulls say
AptarGroup exhibits strong growth potential, particularly within its AMS Solutions segment, which has achieved a compound annual growth rate (CAGR) of approximately 10%, accounting for about 11% of Pharma’s revenue and 5% of total revenue for FY24. The company's Injectables business is experiencing significant growth as well, with a CAGR of 9%, driven by the shift towards biologics and rising demand for GLP-1 medications. This dual growth in specialized segments is expected to contribute to margin expansion, positioning AptarGroup favorably for sustained financial performance.
Bears say
AptarGroup faces a prolonged transition to a majority Pharma focus, which may delay anticipated growth and margin expansion, contributing to a negative outlook. The company operates globally, exposing it to currency fluctuations and economic cycles that can adversely affect demand across its key markets. Additionally, regulatory risks, supply chain vulnerabilities, and the potential loss of competitive advantages due to intellectual property issues further exacerbate concerns regarding the company's financial position.
This aggregate rating is based on analysts' research of Aptargroup and is not a guaranteed prediction by Public.com or investment advice.
Aptargroup (ATR) Analyst Forecast & Price Prediction
Start investing in Aptargroup (ATR)
Order type
Buy in
Order amount
Est. shares
0 shares